In phase 1/2a trials of zorevunersen (STK-001), an antisense oligonucleotide that increases expression of NaV1.1 channels [152], median convulsive seizure frequency was reduced at 3 and 6 months after the last dose compared with baseline in children with SCN1A-positive Dravet syndrome [153,154]. The gene discussed is SCN1A; the disease is Dravet syndrome.